SVB Wealth LLC Decreases Stock Holdings in Henry Schein, Inc. $HSIC

SVB Wealth LLC cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 85.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,003 shares of the company’s stock after selling 16,988 shares during the period. SVB Wealth LLC’s holdings in Henry Schein were worth $227,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Swiss Life Asset Management Ltd lifted its position in Henry Schein by 13.2% in the fourth quarter. Swiss Life Asset Management Ltd now owns 5,787 shares of the company’s stock valued at $437,000 after acquiring an additional 673 shares during the last quarter. Advisor OS LLC lifted its position in Henry Schein by 5.9% in the fourth quarter. Advisor OS LLC now owns 5,743 shares of the company’s stock valued at $434,000 after acquiring an additional 318 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in Henry Schein by 52.8% in the fourth quarter. Sequoia Financial Advisors LLC now owns 12,936 shares of the company’s stock valued at $978,000 after acquiring an additional 4,471 shares during the last quarter. Stevens Capital Management LP purchased a new stake in Henry Schein in the fourth quarter valued at $441,000. Finally, Swedbank AB lifted its position in Henry Schein by 1.0% in the fourth quarter. Swedbank AB now owns 1,312,312 shares of the company’s stock valued at $99,185,000 after acquiring an additional 12,741 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Mark E. Mlotek sold 5,925 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the sale, the executive vice president directly owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the sale, the director directly owned 15,420 shares of the company’s stock, valued at $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 105,911 shares of company stock valued at $8,574,982. 0.89% of the stock is owned by insiders.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $69.45 on Thursday. The company has a 50-day simple moving average of $75.09 and a 200-day simple moving average of $75.21. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The stock has a market capitalization of $7.91 billion, a price-to-earnings ratio of 20.98, a PEG ratio of 1.74 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the prior year, the company earned $1.15 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts predict that Henry Schein, Inc. will post 5.31 EPS for the current year.

Analyst Upgrades and Downgrades

HSIC has been the subject of a number of research reports. Leerink Partners reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Wells Fargo & Company boosted their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. BTIG Research initiated coverage on shares of Henry Schein in a research report on Thursday, April 16th. They issued a “neutral” rating for the company. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $86.83.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.